Pfizer & Abu Dhabi DoH unite to boost clinical trials capabilities

By Shilpa Annie Joseph, Official Reporter
  • Follow author on
Officials from DoH Abu Dhabi and Pfizer during the signing ceremony.

Abu Dhabi’s regulative body of the healthcare sector, Department of Health – Abu Dhabi (DoH) has entered into a partnership with American drugmaker Pfizer to develop national competencies and clinical research capacity in the emirate.

According to the statement, the partnership will focus on improving clinical trial conduct as well as research and medical processes in Abu Dhabi.

Pfizer will assist the Department of Health in developing a training curriculum that is specialized in advancing the early phase of clinical trials and drug development programs.

The partnership underscores the emirate’s ongoing efforts to improve its digital health system and promote healthcare innovation.

As per the statement, “Through this collaboration, Pfizer seeks to train up to 150 clinical researchers who will also have an opportunity of research mentorship support by Pfizer research partner within two years supporting DoH aim of reaching 500 qualified clinical researchers by 2025 through various collaborations and initiatives.”

Dr. Jamal Mohammed Al Kaabi
Dr. Jamal Mohammed Al Kaabi Undersecretary – DoH
Abu Dhabi

“Under our wise leadership, DoH is committed to positioning Abu Dhabi as an incubator for innovation in the field of life sciences and as a leading healthcare destination in the world. We do this by providing a legislative environment that attracts and motivates research and innovation in healthcare, enhancing the means of cooperation that join Abu Dhabi with global partners, and continuing to roll out promising clinical trials and research projects. We are excited for our collaboration with Pfizer which focus on conducting safe and efficient early-stage clinical trials based on international guidelines and global best practices. The partnership contributes to developing our expertise and advancing our capabilities in the UAE which positively impact the health and well-being of individuals worldwide.”

The experts will conduct the training courses from Pfizer, academic institutions, and other specialized partners. The participants will receive training in technologies and artificial intelligence tools that accelerate the drug discovery process.

Ms. Lindsey Dietschi, Cluster Lead of Pfizer Gulf said, “Abu Dhabi established a robust and sustainable world-class healthcare system that fosters innovation in research and development of processes. We believe in the vision of Abu Dhabi that aims to deliver more medical breakthroughs and ensure healthier communities.”

Related: Dubai’s DHCA brings out ‘Masari’ program to empower Emirati workforce